-
Oct 30, 2026Biomarkers in Translational Medicine: Connecting Preclinical Pharmacology Wit...Learn how PK/PD biomarkers, target engagement and cross-species studies connect preclinical pharmacology with clinical dose selection and patient stratification. -
Oct 10, 2026NHP Liver Fibrosis Imaging: MRI-PDFF, MRE And BiopsyLearn what MRI-PDFF, MRE and liver biopsy measure in NHP fibrosis studies, how their endpoints differ, and what model-specific validation is needed. -
Sep 24, 2026MABEL Calculation: Allometric Scaling Of NHP PK To HumanLearn how cynomolgus monkey clearance can be scaled to predict human PK using a 0.85 allometric exponent, and how this supports MABEL dose assessment. -
Sep 23, 2026Why Good In Vitro Data May Underperform In Vivo | Prisys BiotechExplore why strong in vitro results may not translate directly to in vivo exposure and pharmacological activity across different drug modalities. -
Sep 20, 2026How To Interpret PK Parameters in Preclinical Animal StudiesLearn how Cmax, AUC, Tmax, half-life, clearance and other PK parameters are interpreted in preclinical animal studies and PK/PD research. -
Sep 09, 2026Immuno-PET in NHP Models For Antibody DevelopmentLearn how Immuno-PET in NHP models evaluates antibody biodistribution, tissue accessibility, and target engagement for translational drug development. -
Sep 04, 2026Why Good In Vitro Data Can Fail In Vivo: Rethinking DMPK Across Drug ModalitiesWhy do promising in vitro results fail in vivo? Explore how DMPK challenges differ across small molecules, antibodies, ADCs, peptides, and nucleic acids. -
Sep 01, 2026Imaging-Based PK/PD in Non-Human PrimatesLearn how imaging-based PK/PD in NHPs complements plasma PK by evaluating tissue distribution, target engagement, and pharmacodynamic responses.
-
Aug 28, 2026Why Animal Models Succeed Or Fail in Drug DevelopmentWhen each model is selected for a clearly defined purpose, preclinical research becomes more than a demonstration of efficacy
-
Aug 26, 2026Quantitative PET Target Engagement in NHPs For CNS DrugsLearn how quantitative PET in non-human primates measures brain exposure and target occupancy to support CNS drug development, dose selection, and translation. -
Aug 19, 2026PET Biodistribution Imaging in Non-Human PrimatesLearn how PET imaging enables longitudinal biodistribution studies in NHPs, with applications in vaccines, nanoparticles, biologics, and translational drug development. -
Aug 14, 2026PBPK Vs. Compartmental Models: Why PBPK MattersLearn how PBPK modeling differs from traditional PK models and supports DDI, organ impairment, pediatric dosing, food-effect, and regulatory decisions.
